CYPH Soars 52% as EPS Revisions Hit 254.6%
Cypherpunk Technologies (CYPH) led the pack with a 52.3% surge to $1.63 after its next-year EPS growth estimate was revised upward by 172.2 percentage points to 254.6% on August 19. Azitra (AZTR), Bullish (BLSH), Emergent BioSolutions (EBS), and Gemini Space Station (GEMI) also posted double-digit gains, driven by positive earnings revisions and sector momentum.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| CYPH | Healthcare | 2026-08-19 | +172.2pp | +52.3% |
| AZTR | Healthcare | 2026-08-21 | +8.4pp | +30.8% |
| BLSH | Technology | 2026-08-19 | N/A | +23.0% |
| EBS | Healthcare | 2026-08-21 | N/A | +17.5% |
| GEMI | Financial | 2026-08-19 | N/A | +15.5% |
Why did CYPH stock jump in August 2026?
CYPH jumped 52.3% (from $1.07 to $1.63) after its next-year EPS growth estimate was revised up from 82.3% to 254.6% on August 19, a massive 172.2 percentage point boost.
The healthcare sector has been riding a wave of optimism around biotech innovation, and CYPH's revised outlook signals accelerating earnings potential. Despite no specific earnings news in the window, the screener caught the revision early, and price action confirmed the market's confidence. The stock's explosive move reflects investors pricing in a dramatically improved profitability trajectory.
CYPH EPS revision history → · Screener snapshot from 2026-08-19 →
FAQ: CYPH
Why did CYPH stock jump in August 2026?
CYPH jumped 52.3% after analysts revised its next-year EPS growth estimate from 82.3% to 254.6% on August 19, signaling a major earnings turnaround.
Is CYPH a buy after the rally?
CYPH's EPS growth revision to 254.6% suggests strong earnings momentum, but the 52% rally may already price in much of the improvement. Investors should monitor upcoming financials.
What caused CYPH's surge?
The surge was driven by a significant upward revision in CYPH's next-year EPS growth estimate, which jumped by 172.2 percentage points, indicating improved profitability expectations.
Why did AZTR stock jump in August 2026?
AZTR gained 30.8% (from $0.13 to $0.17) after its next-year EPS growth estimate was lifted from 59.6% to 68.0% on August 21, an 8.4 percentage point revision.
While the absolute revision is modest, it underscores a positive earnings trajectory for the healthcare micro-cap. The move occurred without any earnings-specific news, suggesting the market is responding to the revised estimate as a signal of operational improvements. AZTR's gain is notable given its low price, attracting momentum traders.
AZTR EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: AZTR
Why did AZTR stock jump in August 2026?
AZTR rose 30.8% after analysts raised its next-year EPS growth estimate from 59.6% to 68.0% on August 21, indicating stronger expected profitability.
Is AZTR a buy after the rally?
AZTR's EPS revision to 68.0% growth is positive, but its small market cap and 30.8% jump make it speculative. Investors should assess risk tolerance.
What is AZTR's EPS growth estimate?
AZTR's next-year EPS growth estimate is now 68.0%, up from 59.6% prior to the revision.
Why did BLSH stock jump in August 2026?
BLSH jumped 23.0% (from $26.92 to $33.11) after analysts revised its next-year EPS growth estimate to 89.6%, a signal of robust earnings expansion in the technology sector.
The move aligns with a broader tech rally, as investors favor companies with high growth potential. No specific earnings news accompanied the move, but the screener flagged BLSH for its strong revision, and price action confirmed the market's approval. The gain reflects growing confidence in the company's future profitability.
BLSH EPS revision history → · Screener snapshot from 2026-08-19 →
FAQ: BLSH
Why did BLSH stock jump in August 2026?
BLSH rose 23.0% after its next-year EPS growth estimate was revised to 89.6%, signaling strong expected earnings growth in the tech sector.
Is BLSH a buy after the rally?
BLSH's high EPS growth estimate of 89.6% supports a bullish outlook, but the 23% rally may have priced in near-term gains. Investors should watch for earnings execution.
What is BLSH's EPS growth estimate?
BLSH's next-year EPS growth estimate stands at 89.6%, reflecting strong projected earnings expansion.
Why did EBS stock jump in August 2026?
EBS gained 17.5% (from $5.08 to $5.97) after its next-year EPS growth estimate was revised to a staggering 191.0%, one of the highest in the healthcare sector.
The revision, detected on August 21, points to a major earnings inflection for Emergent BioSolutions, which has been restructuring its operations. No earnings news emerged in the window, but the dramatic estimate upgrade likely drove institutional buying. The move underscores the market's appetite for healthcare names with transformative earnings potential.
EBS EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: EBS
Why did EBS stock jump in August 2026?
EBS rose 17.5% after its next-year EPS growth estimate was revised to 191.0%, signaling a massive expected earnings surge.
Is EBS a buy after the rally?
EBS's 191.0% EPS growth estimate suggests a strong earnings turnaround, but the 17.5% gain may reflect early positioning. Investors should evaluate the sustainability of the revision.
What is EBS's EPS growth estimate?
EBS's current next-year EPS growth estimate is 191.0%, indicating expectations of near-tripling earnings.
Why did GEMI stock jump in August 2026?
GEMI climbed 15.5% (from $3.93 to $4.54) after its next-year EPS growth estimate was revised to 25.4%, a solid yet more conservative growth rate compared to peers.
The financial sector has seen steady gains on stabilizing rate expectations, and GEMI's estimate revision adds to the positive sentiment. Without earnings-specific news, the move likely reflects the screener's early detection of improving earnings fundamentals. The 15.5% gain shows investors rewarding even moderate upward revisions in a supportive macro environment.
GEMI EPS revision history → · Screener snapshot from 2026-08-19 →
FAQ: GEMI
Why did GEMI stock jump in August 2026?
GEMI rose 15.5% after its next-year EPS growth estimate was revised to 25.4%, indicating improved earnings expectations in the financial sector.
Is GEMI a buy after the rally?
GEMI's moderate EPS growth of 25.4% may offer balanced risk-reward, but the 15.5% rally demands a check on valuation multiples.
What is GEMI's EPS growth estimate?
GEMI's next-year EPS growth estimate is 25.4%, reflecting steady expected profit growth.
Today's performers highlight the market's strong reaction to upward EPS revisions, particularly in healthcare and tech, where growth expectations are accelerating. The double-digit gains suggest investors are aggressively rewarding companies with improving earnings outlooks, even in the absence of direct news catalysts.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →